WO2002045738A3 - Composicion vacunal que contiene factor de crecimiento transformante alfa - Google Patents

Composicion vacunal que contiene factor de crecimiento transformante alfa Download PDF

Info

Publication number
WO2002045738A3
WO2002045738A3 PCT/CU2001/000011 CU0100011W WO0245738A3 WO 2002045738 A3 WO2002045738 A3 WO 2002045738A3 CU 0100011 W CU0100011 W CU 0100011W WO 0245738 A3 WO0245738 A3 WO 0245738A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
vaccine composition
composition containing
transforming growth
factor alpha
Prior art date
Application number
PCT/CU2001/000011
Other languages
English (en)
French (fr)
Other versions
WO2002045738A2 (es
Inventor
Sierra Aillette Mulet
Rodriguez Rolando Perez
Marinello Gisela Mari Gonzalez
Acosta Anabel Alvarez
Medina Tamara Menendez
Nieto Gerardo Enrique Guillen
Ramirez Belinda Sanchez
Original Assignee
Centro Inmunologia Molecular
Sierra Aillette Mulet
Rodriguez Rolando Perez
Marinello Gisela Mari Gonzalez
Acosta Anabel Alvarez
Medina Tamara Menendez
Nieto Gerardo Enrique Guillen
Ramirez Belinda Sanchez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular, Sierra Aillette Mulet, Rodriguez Rolando Perez, Marinello Gisela Mari Gonzalez, Acosta Anabel Alvarez, Medina Tamara Menendez, Nieto Gerardo Enrique Guillen, Ramirez Belinda Sanchez filed Critical Centro Inmunologia Molecular
Priority to KR1020037007631A priority Critical patent/KR100834383B1/ko
Priority to DE60139633T priority patent/DE60139633D1/de
Priority to NZ526283A priority patent/NZ526283A/en
Priority to EP01999383A priority patent/EP1339425B1/en
Priority to BR0116017-6A priority patent/BR0116017A/pt
Priority to AU2002221520A priority patent/AU2002221520B2/en
Priority to AU2152002A priority patent/AU2152002A/xx
Priority to AT01999383T priority patent/ATE439855T1/de
Priority to MXPA03005031A priority patent/MXPA03005031A/es
Priority to JP2002547521A priority patent/JP2004521091A/ja
Priority to EA200300638A priority patent/EA006240B1/ru
Priority to CA002430621A priority patent/CA2430621A1/en
Publication of WO2002045738A2 publication Critical patent/WO2002045738A2/es
Publication of WO2002045738A3 publication Critical patent/WO2002045738A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición vacunal capaz de producir una respuesta inmune específica contra el TFG alfa autólogo conteniendo como principio activo al TGF alfa o cualquier derivado del mismo y un adyuvante apropiado. El preparado vacunal puede incluir también una combinación del TGF alfa con otros factores del crecimiento, tales como el factor de crecimiento epidérmico, EGF, de manera que inhiba la proliferación de tumores cuya progresión dependa de estos factores. Mediante el uso de esta composición se pueden controlar el crecimiento y proliferación de carconomas epidermoides.
PCT/CU2001/000011 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa WO2002045738A2 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020037007631A KR100834383B1 (ko) 2000-12-06 2001-12-06 전환 성장 인자 알파를 함유하는 백신 조성물
DE60139633T DE60139633D1 (de) 2000-12-06 2001-12-06 Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
NZ526283A NZ526283A (en) 2000-12-06 2001-12-06 Vaccine composition containing human transforming growth factor alpha fused to a carrier protein and optionally contain an EGF-R ligand
EP01999383A EP1339425B1 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
BR0116017-6A BR0116017A (pt) 2000-12-06 2001-12-06 Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo
AU2002221520A AU2002221520B2 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
AU2152002A AU2152002A (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
AT01999383T ATE439855T1 (de) 2000-12-06 2001-12-06 Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
MXPA03005031A MXPA03005031A (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa.
JP2002547521A JP2004521091A (ja) 2000-12-06 2001-12-06 トランスフォーミング増殖因子アルファを含有するワクチン組成物
EA200300638A EA006240B1 (ru) 2000-12-06 2001-12-06 Вакцинная композиция, содержащая трансформирующий фактор роста альфа
CA002430621A CA2430621A1 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU286/2000 2000-12-06
CU20000286A CU23077A1 (es) 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Publications (2)

Publication Number Publication Date
WO2002045738A2 WO2002045738A2 (es) 2002-06-13
WO2002045738A3 true WO2002045738A3 (es) 2003-02-20

Family

ID=34109588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2001/000011 WO2002045738A2 (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa

Country Status (21)

Country Link
US (1) US20030054011A1 (es)
EP (1) EP1339425B1 (es)
JP (1) JP2004521091A (es)
KR (1) KR100834383B1 (es)
CN (2) CN1482916A (es)
AR (1) AR031785A1 (es)
AT (1) ATE439855T1 (es)
AU (2) AU2152002A (es)
BR (1) BR0116017A (es)
CA (1) CA2430621A1 (es)
CU (1) CU23077A1 (es)
DE (1) DE60139633D1 (es)
EA (1) EA006240B1 (es)
ES (1) ES2332125T3 (es)
MX (1) MXPA03005031A (es)
MY (1) MY141122A (es)
NZ (1) NZ526283A (es)
PE (1) PE20020696A1 (es)
UY (1) UY27060A1 (es)
WO (1) WO2002045738A2 (es)
ZA (1) ZA200304416B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101323845B1 (ko) 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CN113855792B (zh) * 2021-12-01 2022-03-01 上海惠盾因泰生物科技有限公司 重组hEGF-CRM197肿瘤治疗性疫苗配制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5690928A (en) * 1990-06-21 1997-11-25 Merck & Co., Inc. Method of treating bladder cancer cells
US5894018A (en) * 1993-12-09 1999-04-13 Centro De Immunologia Molecular Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivative thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5690928A (en) * 1990-06-21 1997-11-25 Merck & Co., Inc. Method of treating bladder cancer cells
US5894018A (en) * 1993-12-09 1999-04-13 Centro De Immunologia Molecular Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivative thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D'ERRICO A ET AL.: "Role and new perspectives of transforming growth factor-alpha (TGF-a1) adenocarcinoma of the gastro-oesophageal junction.", BR J CANCER, vol. 82 (4), February 2000 (2000-02-01), pages 865 - 870, XP002210096 *

Also Published As

Publication number Publication date
ZA200304416B (en) 2004-07-07
EA200300638A1 (ru) 2003-10-30
EA006240B1 (ru) 2005-10-27
CN1482916A (zh) 2004-03-17
US20030054011A1 (en) 2003-03-20
UY27060A1 (es) 2002-03-22
KR100834383B1 (ko) 2008-06-09
EP1339425A2 (en) 2003-09-03
PE20020696A1 (es) 2002-09-19
NZ526283A (en) 2004-11-26
AU2152002A (en) 2002-06-18
ATE439855T1 (de) 2009-09-15
DE60139633D1 (de) 2009-10-01
AU2002221520B2 (en) 2007-10-11
BR0116017A (pt) 2004-01-13
AR031785A1 (es) 2003-10-01
KR20030061424A (ko) 2003-07-18
MY141122A (en) 2010-03-15
EP1339425B1 (en) 2009-08-19
ES2332125T3 (es) 2010-01-27
CA2430621A1 (en) 2002-06-13
CN101406692A (zh) 2009-04-15
CU23077A1 (es) 2005-08-17
WO2002045738A2 (es) 2002-06-13
MXPA03005031A (es) 2004-09-10
JP2004521091A (ja) 2004-07-15

Similar Documents

Publication Publication Date Title
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
WO2006062807A3 (en) Compositions with enhanced immunogenicity
WO2005037190A3 (en) Multiplex vaccines
AU1593001A (en) Recombinant gelatin in vaccines
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
WO2006096614A3 (en) Angiogenic heparin binding peptide amphiphiles
WO2019147749A3 (en) Stabilized rsv f proteins and uses thereof
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2003051401A3 (de) Stabilisierte mrna tumor-vakzine
WO2005032582A3 (en) Immunogenic compositions for streptococcus pyogenes
MXPA04006059A (es) Preparacion liofilizada que contiene anticuerpos contra el receptor del factor de crecimiento epidermico.
WO2004075829A3 (en) Adjuvanted influenza vaccine
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
WO2002045738A3 (es) Composicion vacunal que contiene factor de crecimiento transformante alfa
WO2004030696A3 (en) Composition for vaccination
AU2002217043A1 (en) Salmonella vaccine
EP1621549A3 (en) Compositions of fsh with high sialylation degree and their use for the preparation of medicinaments
CA2131565A1 (en) Organopolysiloxanes Containing Hydrophilic Groups
AU2002217781A1 (en) Occlusion devices
WO2003037371A3 (en) Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
CA2137639A1 (en) Vaccine Composition Comprising Autologous Epidermal Growth Factor or a Fragment or a Derivate Thereof having Anti-Tumor Activity and Use Thereof in the Therapy of Malignant Diseases
AU6636098A (en) Topical composition containing human epidermal growth factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 526283

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005031

Country of ref document: MX

Ref document number: 2003/04416

Country of ref document: ZA

Ref document number: 2430621

Country of ref document: CA

Ref document number: 200304416

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002547521

Country of ref document: JP

Ref document number: 03048135

Country of ref document: CO

Ref document number: 886/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020037007631

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001999383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018214347

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002221520

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200300638

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020037007631

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001999383

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 526283

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526283

Country of ref document: NZ